NeoGenomics Beheer

Beheer criteriumcontroles 3/4

De CEO NeoGenomics is Chris Smith, benoemd in Aug2022, heeft een ambtstermijn van 2.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 11.67M, bestaande uit 8.6% salaris en 91.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.5% van de aandelen van het bedrijf, ter waarde $ 9.93M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 3.8 jaar.

Belangrijke informatie

Chris Smith

Algemeen directeur

US$11.7m

Totale compensatie

Percentage CEO-salaris	8.6%
Dienstverband CEO	2.3yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07

NeoGenomics: Gambling On Growth

Dec 16

Analyse CEO-vergoeding

Hoe is Chris Smith's beloning veranderd ten opzichte van NeoGenomics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$78m
Jun 30 2024	n/a	n/a	-US$79m
Mar 31 2024	n/a	n/a	-US$84m
Dec 31 2023	US$12m	US$1m	-US$88m
Sep 30 2023	n/a	n/a	-US$96m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$126m
Dec 31 2022	US$15m	US$346k	-US$144m

Compensatie versus markt: De totale vergoeding ($USD 11.67M ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.37M ).

Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Chris Smith (61 yo)

2.3yrs

Tenure

US$11,665,946

Compensatie

Mr. Christopher Michael Smith, also known as Chris, serves as Chief Executive Officer at NeoGenomics Laboratories, Inc. since August 2022. He serves as Director at NeoGenomics Laboratories, Inc. since 2023...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Smith	CEO & Director	2.3yrs	US$11.67m	0.50% $ 9.9m
Jeffrey Sherman	Chief Financial Officer	1.9yrs	US$3.55m	0.12% $ 2.3m
Vishal Sikri	President of Advanced Diagnostics	2.8yrs	US$2.37m	0.10% $ 2.0m
Melody Harris	President & COO of Informatics	1.9yrs	US$4.69m	0.084% $ 1.7m
Warren Stone	Chief Commercial Officer	2yrs	US$3.01m	0.078% $ 1.5m
Gregory Aunan	Chief Accounting Officer	1.5yrs	geen gegevens	0.011% $ 222.0k
Kendra Sweeney	Vice President of Investor Relations & Communications	no data	geen gegevens	geen gegevens
Alicia Olivo	Executive VP of Business Development	2.6yrs	geen gegevens	0.033% $ 647.3k
Hutan Hashemi	Chief Compliance Officer	2.6yrs	geen gegevens	geen gegevens
Derek Lyle	Chief Medical Officer	3.8yrs	geen gegevens	geen gegevens
Gary Passman	Chief Culture Officer	1.8yrs	geen gegevens	geen gegevens
Kareem Saad	Head of Strategy & Transformation	less than a year	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NEO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Smith	CEO & Director	2.3yrs	US$11.67m	0.50% $ 9.9m
Michael Kelly	Independent Director	4.3yrs	US$317.50k	0.025% $ 487.8k
Lynn Tetrault	Independent Chair of the Board	9.4yrs	US$365.00k	0.048% $ 943.0k
Bernard Fox	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
Riccardo Dalla-Favera	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
Anthony Zook	Independent Director	1.4yrs	US$276.23k	0.0088% $ 174.1k
Steven Rosen	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
James Downing	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
Stephen Kanovsky	Independent Director	7.3yrs	US$309.20k	0.028% $ 554.4k
Razelle Kurzrock	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
Alison Hannah	Member of Scientific Advisory Board & Independent Director	9.4yrs	US$305.00k	0.093% $ 1.8m
Mark Rubin	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NEO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

NeoGenomics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

NeoGenomics, Inc. Announces Executive Changes

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations

Neogenomics, Inc. Revises Full-Year 2024 Guidance

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q3, 2024 Results on Nov 05, 2024

NeoGenomics, Inc. Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia

Consensus EPS estimates fall by 15%

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

NeoGenomics, Inc. Revises Earnings Guidance for the Full-Year 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. to Report Q2, 2024 Results on Jul 29, 2024

NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO

NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics

NeoGenomics, Inc. to Report Q1, 2024 Results on Apr 30, 2024

NeoGenomics, Inc., Annual General Meeting, May 23, 2024

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Price target increased by 7.2% to US$21.55

Full year 2023 earnings: EPS exceeds analyst expectations

NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024

NeoGenomics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

NeoGenomics Laboratories, Inc. to Appeal Ruling

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Consensus estimates of losses per share improve by 11%

NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neogenomics, Inc. Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

NeoGenomics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. Expands Board of Directors with Appointments of Three Independent Directors

NeoGenomics, Inc.'s RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

NeoGenomics, Inc. and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics, Inc. to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Price target increased by 7.7% to US$21.64

NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.40 loss in 1Q 2022)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics, Inc. Announces Results of a New Study of the RaDaR Assay in Patients with Muscle-Invasive Bladder Cancer

Neogenomics, Inc. Announces Resignation of David J. Daly to Board of Directors

The Klein Law Firm Announces Lead Plaintiff Deadline of February 6, 2023 in the Class Action Filed on Behalf of Neogenomics, Inc. Shareholders

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Gibbs Law Group Announces Files Class Action Lawsuit Against NeoGenomics Inc

NeoGenomics, Inc. Announces Executive Changes

Neogenomics, Inc. Announces Radar Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. Appoints Melody Harris as President, Enterprise Operations effective December 5, 2022

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeoGenomics Appoints David Perez to its Board of Directors

NeoGenomics, Inc. Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch

NeoGenomics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeoGenomics: Market Punishment Continues, But Looks Justified

NeoGenomics grants CEO restricted shares, stock options

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

NeoGenomics, Inc. Appoints Chris Smith as Chief Executive Officer, Effective August 15, 2022

NeoGenomics gets new CEO

Price target decreased to US$17.75

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

NeoGenomics, Inc.(NasdaqCM:NEO) dropped from Russell 2000 Growth-Defensive Index

NeoGenomics, Inc. Announces Resignation of Douglas Brown as Chief Strategy and Corporate Development Officer

Neogenomics, Inc. Announces Executive Changes, Effective May 23, 2022

Consensus EPS estimates fall by 21%

President & COO of Lab Operations notifies of intention to sell stock